Anu Thummala

2.4k total citations · 1 hit paper
12 papers, 1.8k citations indexed

About

Anu Thummala is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Anu Thummala has authored 12 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Anu Thummala's work include Advanced Breast Cancer Therapies (11 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer-related Molecular Pathways (3 papers). Anu Thummala is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), HER2/EGFR in Cancer Research (6 papers) and Cancer-related Molecular Pathways (3 papers). Anu Thummala collaborates with scholars based in United States, Hungary and Germany. Anu Thummala's co-authors include Richard S. Finn, Dennis J. Slamon, Xin Huang, Katalin Boér, Tamás Pintér, Igor Bondarenko, Yaroslav Shparyk, Marcus Schmidt, Ravindranath Patel and Johannes Ettl and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Anu Thummala

12 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

2014 1.4k citations Richard S. Finn, John Crown et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Anu Thummala

Since Specialization

Citations

This map shows the geographic impact of Anu Thummala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anu Thummala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anu Thummala more than expected).

Fields of papers citing papers by Anu Thummala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anu Thummala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anu Thummala. The network helps show where Anu Thummala may publish in the future.

Co-authorship network of co-authors of Anu Thummala

This figure shows the co-authorship network connecting the top 25 collaborators of Anu Thummala. A scholar is included among the top collaborators of Anu Thummala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anu Thummala. Anu Thummala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study 2021 ·Clinical Cancer Research ·Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Jie Xiao, Jessica A. Sorrentino, Janet K. Horton, Joyce O’Shaughnessy	28
2	Abstract PD1-06: Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial 2021 ·Cancer Research ·Joyce O’Shaughnessy, Gail S. Wright, Anu Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Jie Xiao, Jessica A. Sorrentino, Janet K. Horton, Antoinette R. Tan	6
3	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) 2020 ·Breast Cancer Research and Treatment ·Richard S. Finn, Katalin Boér, Igor Bondarenko, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, Олександр Войтко, Eustratios Bananis, Lynn McRoy, Keith D. Wilner, Xin Huang, Sindy Kim, Dennis J. Slamon, Johannes Ettl	111
4	Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial 2019 ·The Lancet Oncology ·Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael Danso, Lazar Popović, Timothy Pluard, Hyo S. Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald Richards, Sharon Wilks, Dušan Milenković, Yang Zhao, Joyce Antal, Shannon R. Morris, Joyce O’Shaughnessy	86
5	Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). 2017 ·Journal of Clinical Oncology ·Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko, (unknown), Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, (unknown), Camilla Fowst, Xin Huang, Sindy Kim, Dennis J. Slamon	53
6	Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18. 2015 ·Journal of Clinical Oncology ·Richard S. Finn, John Crown, Johannes Ettl, Tamás Pintér, Anu Thummala, Yaroslav Shparyk, Ravi Patel, Sophia Randolph, Sindy Kim, Xin Huang, Yuqiu Jiang, Cynthia Huang Bartlett, Dennis J. Slamon	1
7	The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/ HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study. 2015 ·Journal of Clinical Oncology ·Richard S. Finn, John Crown, István Láng, (unknown), Marcus Schmidt, Ravi Patel, Anu Thummala, Igor Bondarenko, Sophia Randolph, Sindy Kim, Xin Huang, (unknown), Cynthia Huang Bartlett, Dennis J. Slamon	3
8	Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18). 2015 ·Journal of Clinical Oncology ·Dennis J. Slamon, John Crown, István Láng, (unknown), Marcus Schmidt, Ravi Patel, Anu Thummala, (unknown), Sophia Randolph, Sindy Kim, Xin Huang, Cynthia Huang Bartlett, Patrick Schnell, Richard S. Finn	6
9	Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial. 2015 ·Journal of Clinical Oncology ·John Crown, Richard S. Finn, Johannes Ettl, Katalin Boér, Ravi Patel, Anu Thummala, Sophia Randolph, Sindy Kim, Xin Huang, Sashi Nadanaciva, Patrick Schnell, Cynthia Huang Bartlett, Dennis J. Slamon	4
10	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study breakdown → 2014 ·The Lancet Oncology ·Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko, (unknown), Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, (unknown), Camilla Fowst, Xin Huang, Sindy T. Kim, Sophia Randolph, Dennis J. Slamon	1412
11	Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18) 2014 ·Cancer Research ·Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko, (unknown), Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, (unknown), Xin Huang, Sindy T. Kim, Sophia Randolph, Dennis J. Slamon	37
12	Randomized phase II trial of preoperative chemoradiotherapy with or without cetuximab in locally advanced rectal adenocarcinoma. 2014 ·Journal of Clinical Oncology ·Andrea M. McCollum, Darren M. Kocs, (unknown), (unknown), Thomas E. Boyd, (unknown), (unknown), James F. Sanchez, M. Simon, Paramjeet Singh, Anu Thummala, Svetislava J. Vukelja, Yunfei Wang, Lina Asmar, Donald Richards	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact